Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer

Inclusion Criteria: * Gastric adenocarcinoma diagnosed by histology. * Ambulatory cases, 18-75 years old * ECOG performance status ≤ 1 * Have not received anti-tumor therapy previously (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy) * Patients able to tolerate abdominal surgery above grade 3 * Has adequate organ function as defined by the following criteria: * WBC\> 4.0×10\^9/L * ANC\> 1.5×10\^9/L * ANC ≥ 1.5×10\^9/L * HB ≥ 80 g/L * PLT ≥ 100×10\^9/L * TBIL ≤ 1.5×ULN * ALT and AST \<2.5 × ULN, for patients with liver metastases, ALT and AST \<5 × ULN * BUN and Cr ≤ 1.5 × ULN or endogenous creatinine clearance ≥ 50 mL/min * No history of other tumors * Be willing and able to comply with the plan during the research period * Has given written informed consent * Life expectancy ≥ 6 months Exclusion Criteria: * Those with a history of other malignancies in the last 5 years, except for cured non-melanoma skin cancer and cervical carcinoma in situ * HER-2+ and willing to receive Trastuzumab * Pregnancy or breast-feeding women; Men and women who are sexually active (possible to have children) and unwilling to use contraception during the study period * Severe, uncontrolled medical diseases and infections; chronic bowel disease or short bowel syndrome * Major organ failure, such as compensatory cardiopulmonary liver and kidney failure; severe liver and kidney metabolism abnormalities, affecting the normal metabolism of drugs * Patients with other surgical contraindications, such as serious diseases that are difficult to control * The researcher believes that patients with a clear gastrointestinal bleeding tendency and/or patients with abnormal blood coagulation function (INR \> 1.5) * Active HBV or HCV * Peripheral neuropathy ≥ Grade 2 according to NCT-CTC AE5.0 * Patients who are allergic to the drugs in this study, or determined by the investigator as unsuitable to participate in this clinical study